阿片使用障碍中的正性情绪失调及正念导向恢复增强的normalization效应:一项随机临床试验的二次分析
这项随机临床试验的机制性子研究纳入160名慢性疼痛患者(98例符合阿片使用障碍(OUD)标准),发现OUD+患者在进行正性情绪调节时顶叶晚正电位(LPP)和P300波幅降低,且LPP钝化介导了OUD状态与阿片渴求升高的关联。在62例高危患者中,正念导向恢复增强(MORE)相比支持性团体治疗能更大程度提升调节时的LPP波幅,并改善正性注意、正性情绪和快感缺失,同时减少渴求。
要点
- OUD患者正性情绪调节时LPP和P300波幅降低,且LPP钝化介导OUD与渴求升高关联。
- MORE干预可提升调节时的LPP波幅,并改善正性注意、正性情绪和快感缺失。
- MORE较支持性团体治疗更有效减少阿片渴求,正性情绪调节效能越高随访渴求越低。
核心结论
- 慢性疼痛患者的OUD以正性情绪调节困难为特征,表现为显著性检测和情绪精细加工的神经生理标记异常。
- 通过MORE训练正念和品味可增强正性情绪调节,进而减少渴求,提示normalize奖赏系统功能可能改善OUD。
研究设计与样本
- 随机临床试验的机制性子研究,从犹他州初级保健和疼痛诊所招募慢性疼痛患者,分为符合OUD标准(OUD+)和不符合(OUD-)两组。
- 160名参与者完成正性情绪调节任务和问卷,其中62名有阿片误用风险者按1:1随机接受8周MORE或支持性团体治疗,并在治疗后和3个月随访时评估。
主要发现
- OUD+组在调节相比观看试次时LPP反应低于OUD-组(B=1.91;95%CI 0.85-2.96;P<.001),P300也显示显著组×策略交互(B=1.40;95%CI 0.14-2.67;P=.03)。
- 正性情绪调节时LPP钝化介导了OUD状态与阿片渴求升高的关联。
- MORE组较支持性团体组在调节相比观看试次时LPP增幅更大(B=1.53;95%CI 0.33-2.73;P=.01)。
- MORE较支持性团体组更大程度改善正性信息注意(B=1.32;95%CI 1.14-5.57;P=.004)、正性情绪(B=4.73;95%CI 1.22-8.24;P=.01)和快感缺失(B=2.94;95%CI 0.58-5.31;P=.02),并减少渴求(B=-10.88;95%CI -21.29至-0.48;P=.04)。
- 正性情绪调节效能越高,随访时渴求越低(B=-2.38;95%CI -4.55至-0.21;P=.03)。
临床怎么用
- 在慢性疼痛合并OUD患者中,可关注正性情绪调节困难作为潜在治疗靶点。
- MORE可作为改善正性情绪调节、减少阿片渴求的干预选择。
- 神经生理标记(LPP、P300)可用于评估正性情绪调节及干预效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It remains unknown whether difficulties in positive emotion regulation (ER) drive opioid use disorder (OUD) and whether these difficulties may be remediated. OBJECTIVE: To test whether OUD is associated with attenuated positive ER and whether such positive emotion dysregulation may be treated by mindfulness-based intervention. DESIGN, SETTING, AND PARTICIPANTS: In this mechanistic substudy of a randomized clinical trial, patients with chronic pain who did and did not meet criteria for OUD (OUD+ and OUD-, respectively) were recruited from primary care and pain clinics in Utah from January 2016 to and January 2020 and completed a positive ER task and questionnaires. A subsample of participants at risk for opioid misuse were randomized 1:1 to 8 weeks of Mindfulness-Oriented Recovery Enhancement (MORE) or supportive group (SG) therapy and then completed the ER task at posttreatment and questionnaires through 3-month follow-up. Data were analyzed from December 2022 to June 2024. MAIN OUTCOMES AND MEASURES: The primary mechanistic outcome was parietal late positive potential (LPP) and P300 amplitude during positive ER. Secondary outcomes included self-reported anhedonia, positive affect, attention to positive information, and opioid craving. RESULTS: The 160 participants used opioids for a mean (SD) duration of 9.7 (8.4) years, and 98 participants (61.3%) were classified as OUD+. Mean (SD) participant age was 53.7 (11.9) years, and 102 participants (63.8%) were female. A significant group × task strategy (View, Regulate) interaction was observed during positive ER, characterized by the OUD+ group exhibiting lower LPP responses during Regulate compared to View trials relative to the OUD- group (B = 1.91; 95% CI, 0.85-2.96; P < .001). A significant group × strategy interaction was also observed for the P300 (B = 1.40; 95% CI, 0.14-2.67; P = .03). LPP blunting during positive ER mediated the association between OUD status and elevated opioid craving. In the treatment subsample (n = 62), patients treated with MORE showed greater increases in the LPP during Regulate compared with View trials than patients treated with SG (B = 1.53; 95% CI, 0.33-2.73; P = .01). Additionally, MORE improved attention to positive information (B = 1.32; 95% CI, 1.14-5.57; P = .004), positive affect (B = 4.73; 95% CI, 1.22-8.24; P = .01), and anhedonia (B = 2.94; 95% CI, 0.58-5.31; P = .02) while reducing craving (B = -10.88; 95% CI, -21.29 to -0.48; P = .04) to a greater extent than SG. Higher positive ER efficacy predicted lower craving at follow-up (B = -2.38; 95% CI, -4.55 to -0.21; P = .03). CONCLUSIONS AND RELEVANCE: OUD among patients with chronic pain is characterized by difficulties in positive ER, evident in neurophysiological markers of salience detection and emotional elaboration. In this study, training in mindfulness and savoring via MORE enhanced positive ER, which in turn reduced craving, indicating that interventions that normalize reward system function may remediate OUD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02602535.
引用
- Garland EL, Hudak J, Hanley AW, et al. Positive Emotion Dysregulation in Opioid Use Disorder and Normalization by Mindfulness-Oriented Recovery Enhancement: A Secondary Analysis of a Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40305010. doi:10.1001/jamapsychiatry.2025.0569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。